FilingReader Intelligence
Everest Medicines invests $30.9m in I-Mab biotech stake
August 1, 2025 at 12:31 PM UTC•By FilingReader AI
Everest Medicines subscribed for 15.8 million American depositary shares of I-Mab at $1.95 per share, totaling $30.9 million.
The transaction gives Everest Medicines approximately 16.1% of I-Mab's enlarged share capital, strengthening its biopharmaceutical portfolio alongside existing products including NEFECON, XERAVA, and VELSIPITY.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Everest Medicines publishes news
Free email notifications • Unsubscribe anytime